U.S. Antimicrobial Advisory Board backs Gilead Descovy to reduce risk of HIV infection
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
AIDS is an infectious disease caused by HIV infectionThe development of modern antiviraldrug(http://and the rise of "cocktail therapy" has allowed HIV-infected people to control their condition over a long period of time and achieve a life expectancy comparable to that of normal peopleToday, Gilead Science(http://) announced today that the
(http://Committee (AMDAC) voted 16 to 2 to support Descovy as a pre-exposure prophylaxis (PrEP) therapy to reduce the risk of HIV infection in men and transgender women who have sex with menAbout DescovyDescovy Scientific developed Descovy (F/TAF) as a composite tablet made up of emtricitabine and tenofovir alafenamide, which has been approved for the treatment of AIDSDescovy's potential as APREP therapy has been demonstrated in the discover
trial(http://For discover
In the DISCOVER trial, Descovy compared it with the approved PrEP therapy Truvada (F/TDF) to see if Descovy's ability to reduce the risk of disease in the population met non-performance criteria The results showed that the average risk of HIV infection in the Descovy group was 0.16 per 100 per year, while the average rate of HIV infection in the Truvada group was 0.34 per 100 per year Descovy meets the standard of non-disadvantage compared to Truvada The bone density and renal function safety performance in the Descovy group was significantly better than that of the Truvada group
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
